1h9u › Citations

The structural basis for the specificity of retinoid-X receptor-selective agonists: new insights into the role of helix H12.

Love JD, Gooch JT, Benko S, Li C, Nagy L, Chatterjee VK, Evans RM, Schwabe JW
J Biol Chem 277 11385-91 (2002)
Cited: 51 times
EuropePMC logo PMID: 11782480

Abstract

Ligands that specifically target retinoid-X receptors (RXRs) are emerging as potentially powerful therapies for cancer, diabetes, and the lowering of circulatory cholesterol. To date, RXR has only been crystallized in the absence of ligand or with the promiscuous ligand 9-cis retinoic acid, which also activates retinoic acid receptors. Here we present the structure of hRXRbeta in complex with the RXR-specific agonist LG100268 (LG268). The structure clearly reveals why LG268 is specific for the RXR ligand binding pocket and will not activate retinoic acid receptors. Intriguingly, in the crystals, the C-terminal "activation" helix (AF-2/helix H12) is trapped in a novel position not seen in other nuclear receptor structures such that it does not cap the ligand binding cavity. Mammalian two-hybrid assays indicate that LG268 is unable to release co-repressors from RXR unless co-activators are also present. Together these findings suggest that RXR ligands may be inefficient at repositioning helix H12.

Reviews - 1h9u mentioned but not cited (1)

  1. The retinoid X receptors and their ligands. Dawson MI, Xia Z. Biochim Biophys Acta 1821 21-56 (2012)

Articles - 1h9u mentioned but not cited (14)

  1. Crystal structure of the heterodimeric complex of LXRalpha and RXRbeta ligand-binding domains in a fully agonistic conformation. Svensson S, Ostberg T, Jacobsson M, Norström C, Stefansson K, Hallén D, Johansson IC, Zachrisson K, Ogg D, Jendeberg L. EMBO J 22 4625-4633 (2003)
  2. A system-level investigation into the mechanisms of Chinese Traditional Medicine: Compound Danshen Formula for cardiovascular disease treatment. Li X, Xu X, Wang J, Yu H, Wang X, Yang H, Xu H, Tang S, Li Y, Yang L, Huang L, Wang Y, Yang S. PLoS One 7 e43918 (2012)
  3. The "Phantom Effect" of the Rexinoid LG100754: structural and functional insights. Sato Y, Ramalanjaona N, Huet T, Potier N, Osz J, Antony P, Peluso-Iltis C, Poussin-Courmontagne P, Ennifar E, Mély Y, Dejaegere A, Moras D, Rochel N. PLoS One 5 e15119 (2010)
  4. Emodin regulates neutrophil phenotypes to prevent hypercoagulation and lung carcinogenesis. Li Z, Lin Y, Zhang S, Zhou L, Yan G, Wang Y, Zhang M, Wang M, Lin H, Tong Q, Duan Y, Du G. J Transl Med 17 90 (2019)
  5. Deuterium exchange and mass spectrometry reveal the interaction differences of two synthetic modulators of RXRalpha LBD. Yan X, Pérez E, Leid M, Schimerlik MI, de Lera AR, Deinzer ML. Protein Sci 16 2491-2501 (2007)
  6. Dynamic clustering threshold reduces conformer ensemble size while maintaining a biologically relevant ensemble. Yongye AB, Bender A, Martínez-Mayorga K. J Comput Aided Mol Des 24 675-686 (2010)
  7. Preference of small molecules for local minimum conformations when binding to proteins. Wang Q, Pang YP. PLoS One 2 e820 (2007)
  8. Modeling, synthesis, and biological evaluation of potential retinoid X receptor (RXR) selective agonists: novel analogues of 4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethynyl]benzoic acid (bexarotene) and (E)-3-(3-(1,2,3,4-tetrahydro-1,1,4,4,6-pentamethylnaphthalen-7-yl)-4-hydroxyphenyl)acrylic acid (CD3254). Jurutka PW, Kaneko I, Yang J, Bhogal JS, Swierski JC, Tabacaru CR, Montano LA, Huynh CC, Jama RA, Mahelona RD, Sarnowski JT, Marcus LM, Quezada A, Lemming B, Tedesco MA, Fischer AJ, Mohamed SA, Ziller JW, Ma N, Gray GM, van der Vaart A, Marshall PA, Wagner CE. J Med Chem 56 8432-8454 (2013)
  9. Modeling, synthesis and biological evaluation of potential retinoid X receptor-selective agonists: novel halogenated analogues of 4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethynyl]benzoic acid (bexarotene). Furmick JK, Kaneko I, Walsh AN, Yang J, Bhogal JS, Gray GM, Baso JC, Browder DO, Prentice JL, Montano LA, Huynh CC, Marcus LM, Tsosie DG, Kwon JS, Quezada A, Reyes NM, Lemming B, Saini P, van der Vaart A, Groy TL, Marshall PA, Jurutka PW, Wagner CE. ChemMedChem 7 1551-1566 (2012)
  10. A structural signature motif enlightens the origin and diversification of nuclear receptors. Beinsteiner B, Markov GV, Erb S, Chebaro Y, McEwen AG, Cianférani S, Laudet V, Moras D, Billas IML. PLoS Genet 17 e1009492 (2021)
  11. Comprehensive Set of Tertiary Complex Structures and Palmitic Acid Binding Provide Molecular Insights into Ligand Design for RXR Isoforms. Chaikuad A, Pollinger J, Rühl M, Ni X, Kilu W, Heering J, Merk D. Int J Mol Sci 21 E8457 (2020)
  12. Probabilistic Pocket Druggability Prediction via One-Class Learning. Aguti R, Gardini E, Bertazzo M, Decherchi S, Cavalli A. Front Pharmacol 13 870479 (2022)
  13. Deciphering Risperidone-Induced Lipogenesis by Network Pharmacology and Molecular Validation. Fu Y, Yang K, Huang Y, Zhang Y, Li S, Li WD. Front Psychiatry 13 870742 (2022)
  14. The protein kinase promiscuities in the cancer-preventive mechanisms of NSAIDs. Norvaisas P, Chan D, Yokoi K, Dave B, Ziemys A. Eur J Cancer Prev 25 77-84 (2016)


Reviews citing this publication (4)

  1. Deciphering the nuclear bile acid receptor FXR paradigm. Modica S, Gadaleta RM, Moschetta A. Nucl Recept Signal 8 e005 (2010)
  2. Ligand control of coregulator recruitment to nuclear receptors. Nettles KW, Greene GL. Annu Rev Physiol 67 309-333 (2005)
  3. Structural and functional insights into nuclear receptor signaling. Jin L, Li Y. Adv Drug Deliv Rev 62 1218-1226 (2010)
  4. Nuclear Receptors as Multiple Regulators of NLRP3 Inflammasome Function. Alatshan A, Benkő S. Front Immunol 12 630569 (2021)

Articles citing this publication (32)

  1. Coactivator binding promotes the specific interaction between ligand and the pregnane X receptor. Watkins RE, Davis-Searles PR, Lambert MH, Redinbo MR. J Mol Biol 331 815-828 (2003)
  2. Coupling of receptor conformation and ligand orientation determine graded activity. Bruning JB, Parent AA, Gil G, Zhao M, Nowak J, Pace MC, Smith CL, Afonine PV, Adams PD, Katzenellenbogen JA, Nettles KW. Nat Chem Biol 6 837-843 (2010)
  3. Allosteric control of ligand selectivity between estrogen receptors alpha and beta: implications for other nuclear receptors. Nettles KW, Sun J, Radek JT, Sheng S, Rodriguez AL, Katzenellenbogen JA, Katzenellenbogen BS, Greene GL. Mol Cell 13 317-327 (2004)
  4. A permissive retinoid X receptor/thyroid hormone receptor heterodimer allows stimulation of prolactin gene transcription by thyroid hormone and 9-cis-retinoic acid. Castillo AI, Sánchez-Martínez R, Moreno JL, Martínez-Iglesias OA, Palacios D, Aranda A. Mol Cell Biol 24 502-513 (2004)
  5. On the Utility of ToxCast™ and ToxPi as Methods for Identifying New Obesogens. Janesick AS, Dimastrogiovanni G, Vanek L, Boulos C, Chamorro-García R, Tang W, Blumberg B. Environ Health Perspect 124 1214-1226 (2016)
  6. A transcriptionally silent RXRalpha supports early embryonic morphogenesis and heart development. Mascrez B, Ghyselinck NB, Chambon P, Mark M. Proc Natl Acad Sci U S A 106 4272-4277 (2009)
  7. Live-cell fluorescence correlation spectroscopy dissects the role of coregulator exchange and chromatin binding in retinoic acid receptor mobility. Brazda P, Szekeres T, Bravics B, Tóth K, Vámosi G, Nagy L. J Cell Sci 124 3631-3642 (2011)
  8. Identification of an N-oxide pyridine GW4064 analog as a potent FXR agonist. Feng S, Yang M, Zhang Z, Wang Z, Hong D, Richter H, Benson GM, Bleicher K, Grether U, Martin RE, Plancher JM, Kuhn B, Rudolph MG, Chen L. Bioorg Med Chem Lett 19 2595-2598 (2009)
  9. Synthetic retinoids: structure-activity relationships. Barnard JH, Collings JC, Whiting A, Przyborski SA, Marder TB. Chemistry 15 11430-11442 (2009)
  10. Defining the communication between agonist and coactivator binding in the retinoid X receptor α ligand binding domain. Boerma LJ, Xia G, Qui C, Cox BD, Chalmers MJ, Smith CD, Lobo-Ruppert S, Griffin PR, Muccio DD, Renfrow MB. J Biol Chem 289 814-826 (2014)
  11. Ligand binding shifts highly mobile retinoid X receptor to the chromatin-bound state in a coactivator-dependent manner, as revealed by single-cell imaging. Brazda P, Krieger J, Daniel B, Jonas D, Szekeres T, Langowski J, Tóth K, Nagy L, Vámosi G. Mol Cell Biol 34 1234-1245 (2014)
  12. Crystal structure of a novel tetrameric complex of agonist-bound ligand-binding domain of Biomphalaria glabrata retinoid X receptor. de Groot A, de Rosny E, Juillan-Binard C, Ferrer JL, Laudet V, Pierce RJ, Pebay-Peyroula E, Fontecilla-Camps JC, Borel F. J Mol Biol 354 841-853 (2005)
  13. Analysis of ligand-dependent recruitment of coactivator peptides to RXRbeta in a time-resolved fluorescence resonance energy transfer assay. Stafslien DK, Vedvik KL, De Rosier T, Ozers MS. Mol Cell Endocrinol 264 82-89 (2007)
  14. Structure basis of bigelovin as a selective RXR agonist with a distinct binding mode. Zhang H, Li L, Chen L, Hu L, Jiang H, Shen X. J Mol Biol 407 13-20 (2011)
  15. Structural and functional insights into the ligand-binding domain of a nonduplicated retinoid X nuclear receptor from the invertebrate chordate amphioxus. Tocchini-Valentini GD, Rochel N, Escriva H, Germain P, Peluso-Iltis C, Paris M, Sanglier-Cianferani S, Van Dorsselaer A, Moras D, Laudet V. J Biol Chem 284 1938-1948 (2009)
  16. Design, synthesis, and evaluation of non-steroidal farnesoid X receptor (FXR) antagonist. Kainuma M, Makishima M, Hashimoto Y, Miyachi H. Bioorg Med Chem 15 2587-2600 (2007)
  17. Structure, energetics, and dynamics of binding coactivator peptide to the human retinoid X receptor α ligand binding domain complex with 9-cis-retinoic acid. Xia G, Boerma LJ, Cox BD, Qiu C, Kang S, Smith CD, Renfrow MB, Muccio DD. Biochemistry 50 93-105 (2011)
  18. Inhibition of 1,25-dihydroxyvitamin D3-dependent transcription by synthetic LXXLL peptide antagonists that target the activation domains of the vitamin D and retinoid X receptors. Pathrose P, Barmina O, Chang CY, McDonnell DP, Shevde NK, Pike JW. J Bone Miner Res 17 2196-2205 (2002)
  19. The effect of antagonists on the conformational exchange of the retinoid X receptor alpha ligand-binding domain. Lu J, Dawson MI, Hu QY, Xia Z, Dambacher JD, Ye M, Zhang XK, Li E. Magn Reson Chem 47 1071-1080 (2009)
  20. Synergic effect of vitamin A and high-fat diet in adipose tissue development and nuclear receptor expression in young rats. Redonnet A, Ferrand C, Bairras C, Higueret P, Noël-Suberville C, Cassand P, Atgié C. Br J Nutr 100 722-730 (2008)
  21. Alternative farnesoid structures induce different conformational outcomes upon the Drosophila ortholog of the retinoid X receptor, ultraspiracle. Wozniak M, Chu Y, Fang F, Xu Y, Riddiford L, Jones D, Jones G. Insect Biochem Mol Biol 34 1147-1162 (2004)
  22. The molecular basis of the interactions between synthetic retinoic acid analogues and the retinoic acid receptors. Haffez H, Chisholm DR, Valentine R, Pohl E, Redfern C, Whiting A. Medchemcomm 8 578-592 (2017)
  23. Investigation of ligand interactions with human RXRalpha by hydrogen/deuterium exchange and mass spectrometry. Yan X, Deinzer ML, Schimerlik MI, Broderick D, Leid ME, Dawson MI. J Am Soc Mass Spectrom 17 1510-1517 (2006)
  24. Synthetic LXXLL peptide antagonize 1,25-dihydroxyvitamin D3-dependent transcription. Pike JW, Pathrose P, Barmina O, Chang CY, McDonnell DP, Yamamoto H, Shevde NK. J Cell Biochem 88 252-258 (2003)
  25. Aza-retinoids as novel retinoid X receptor-specific agonists. Farmer LJ, Marron KS, Canan Koch SS, Hwang CK, Kallel EA, Zhi L, Nadzan AM, Robertson DW, Bennani YL. Bioorg Med Chem Lett 16 2352-2356 (2006)
  26. Control of Redox-Active Ester Reactivity Enables a General Cross-Electrophile Approach to Access Arylated Strained Rings. Salgueiro DC, Chi BK, Guzei IA, García-Reynaga P, Weix DJ. Angew Chem Int Ed Engl 61 e202205673 (2022)
  27. Designed Spiroketal Protein Modulation. Scheepstra M, Andrei SA, Unver MY, Hirsch AKH, Leysen S, Ottmann C, Brunsveld L, Milroy LG. Angew Chem Int Ed Engl 56 5480-5484 (2017)
  28. Equilibrium unfolding of the retinoid X receptor ligand binding domain and characterization of an unfolding intermediate. Harder ME, Malencik DA, Yan X, Broderick D, Leid M, Anderson SR, Deinzer ML, Schimerlik MI. Biophys Chem 141 1-10 (2009)
  29. Molecular dynamics simulations and molecular flooding studies of the retinoid X-receptor ligand binding domain. Gray GM, Ma N, Wagner CE, van der Vaart A. J Mol Model 23 98 (2017)
  30. Effects of LG268 on Cell Proliferation and Apoptosis of NB4 Cells. Xu T, Zhong L, Gan LG, Xiao CL, Shan ZL, Yang R, Song H, Li L, Liu BZ. Int J Med Sci 13 517-523 (2016)
  31. Identification of ligand binding site on RXRγ using molecular docking and dynamics methods. Zhao P, Liao QH, Ren CF, Wei J. J Mol Model 17 1259-1265 (2011)
  32. Structural overview and perspectives of the nuclear receptors, a major family as the direct targets for small-molecule drugs. Li F, Song C, Zhang Y, Wu D. Acta Biochim Biophys Sin (Shanghai) 54 12-24 (2022)


Quick links